B
Bull
Bull · 25%IQV
$150.52
Precio del escenario
$261.750
-0.628 (-0.24%)Al cierre
Loading chart…
- High
- 262.820
- Open
- 260.550
- VWAP
- 260.88
- Vol
- 1.84M
- Mkt Cap
- 38.76B
- Low
- 258.080
- Amount
- 480.59M
- EV/EBITDA, TTM
- 16.02
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.
AI analysis of IQVIA Holdings Inc (IQV)
buyIQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.
Analyst Ratings (17)
-1.31% downside
Buy
9 Buy
8 Hold
0 Sell
Current: 261.75
Mínimo
215.00
Promedio
258.31
Máximo
290.00
TD Cowen
Buy
$288
2026-07-29
TD Cowen
2026-07-29
Precio objetivo
$288
Buy
BofA
Buy
$280
2026-07-29
BofA
2026-07-29
Precio objetivo
$280
Buy
RBC Capital
Outperform
$247
2026-07-29
RBC Capital
2026-07-29
Precio objetivo
$247
Outperform
BMO Capital
Outperform
$270
2026-07-29
BMO Capital
2026-07-29
Precio objetivo
$270
Outperform
JPMorgan
Overweight
$285
2026-07-29
JPMorgan
2026-07-29
Precio objetivo
$285
Overweight
Métricas de valoración
The current forward P/E ratio for IQVIA Holdings Inc (IQV) is 20.28, compared to its 5-year average forward P/E of 19.19.
Alphio AI Price Scenarios for IQV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding IQV
Cronología de eventos
Noticias
3.508-27NewsfilterIQVIA Recognized with Multiple Industry Awards for AI Innovations
- 3.508-20Newsfilter
IQVIA's AI Tool Wins 2026 Breakthrough Award
- 6.508-17Newsfilter
IQVIA Ranked No. 1 in Everest Group's 2026 Pharmaceutical Technology Providers
5.008-02NASDAQ.COMIQVIA Executive Sells 558 Shares at $245.21 Each
5.008-02NASDAQ.COMIQVIA Executive Sells 5,000 Shares, Reducing Holdings by 19%
IQV FAQ — answered by Alphio AI
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
IQVIA Holdings Inc is a good buy right now due to its current price of $261.75, which is below the analyst price target of $288 from TD Cowen, suggesting a potential upside of 9.93%. Additionally, the company's forward P/E ratio of 20.28 indicates reasonable valuation compared to its growth prospects. However, the main risk is the insider selling activity, with a 1004.81% increase in insider selling over the last month, which may signal caution among executives.
17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.